


Technical Information about 8- Bromo- cyclic adenosine diphosphate ribose

Update: May 12, 2011 AI



Abbreviation: **8-Br-cADPR**

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
C ₁₅ H ₂₀ BrN ₅ O ₁₃ P ₂ (free acid)	[151898-26-9]	620.2 (free acid)	λ _{max} 264 nm / ε 15730 / pH 7	B 065

Name: 8- Bromo- cyclic adenosine diphosphate ribose / 8- Bromo- cyclic adenosine diphosphoribose

Description: 8-Br-cADPR is an analogue of the second messenger cyclic adenosine diphosphate ribose (cADPR, BIOLOG Cat. No. C 005) in which the hydrogen in position 8 of the heterocyclic nucleobase is replaced by bromine.

Properties: Antagonist of the second messenger cADPR.

Specification: Crystallized or lyophilized sodium salt. Contains no buffer salts. The free acid or other salt forms are available upon request. Please keep in mind that equal concentrations of the compound may look different in volume due to sensitivity of the lyophilized form to humidity. The compound can even contract to small volume droplets. Normally the product is located in the conical bottom of the tube. Micromolar quantities are determined by UV at λ_{max}.

Purity: Typical analysis is better than 97% (HPLC / UV / 264 nm). The product is not sterile and has not been tested for endotoxins.

Solubility: 8-Br-cADPR has excellent solubility in water and aqueous buffers. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing. When opening the tube please make sure that no substance is lost within the cap.

Stability and Storage: 8-Br-cADPR has limited stability at ambient temperature. Therefore, we recommend that the compound should be stored in the freezer (-20° celsius necessary, -80° recommended), for longer storage periods preferably in freeze-dried form.

Toxicity and Safety: Since cADPR seems to have tasks in every organism, it is not unlikely that its analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with, no health hazards have been reported. Nevertheless please keep in mind, that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.

Our products are designed, developed and sold for research purposes only! They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.

Not for drug, household or related uses!

Selected References for 8-Br-cADPR:

Rah, S.-Y.; Mushtaq, M.; Nam, T.-S.; Kim, S.H.; Kim, U.-H., *J. Biol. Chem.*, **285**, 21877 - 21887 (2010): "Generation of Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate by CD38 for Ca²⁺ Signaling in Interleukin-8-treated Lymphokine-activated Killer Cells"

Mayo, L.; Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.; Moutin, M.-J.; Lund, F.E.; Stein, R., *J. Immunol.*, **181**, 92 - 103 (2008): "Dual Role of CD38 in Microglial Activation and Activation-induced Cell Death"

Kirchberger, T.; Wagner, G.; Xu, J.; Cordiglieri, C.; Wang, P.; Gasser, A.; Fliegert, R.; Bruhn, S.; Flügel, A.; Lund, F.E.; Zhang, L.-h.; Potter, B.V.L.; Guse, A.H., *Br. J. Pharmacol.*, **149**, 337 - 344 (2006): "Cellular Effects and Metabolic Stability of N1-cyclic Inosine Diphosphoribose and its Derivatives"

Guse, A.H.; Gu, X.; Zhang, L.; Weber, K.; Krämer, E.; Yang, Z.; Jin, H.; Li, Q.; Carrier, L.; Zhang, L., *J. Biol. Chem.*, **280**, 15952 - 15959 (2005): "A Minimal Structural Analogue of Cyclic ADP-ribose - Synthesis and Calcium Release Activity in Mammalian Cells"

Guse, A.H., *FEBS J.*, **272**, 4590 - 4597 (2005): "Second Messenger Function and the Structure-activity Relationship of Cyclic Adenosine Diphosphoribose (cADPR)"

Hashii, M.; Shuto, S.; Fukuoka, M.; Kudoh, T.; Matsuda, A.; Higashida, H., *J. Neurochem.*, **94**, 316 - 323 (2005): "Amplification of Depolarization-induced and Ryanodine-sensitive Cytosolic Ca²⁺ Elevation by Synthetic Carbocyclic Analogs of Cyclic ADP-ribose and Their Antagonistic Effects in NG108-15 Neuronal Cells"

Partida-Sanchez, S.; Iribarren, P.; Moreno-Garcia, M.E.; Gao, J.-L.; Murphy, P.M.; Oppenheimer, N.; Wang, J.M.; Lund, F.E., *J. Immunol.*, **172**, 1896 - 1906 (2004): "Chemotaxis and Calcium Responses of Phagocytes to Formyl Peptide Receptor Ligands is Differentially Regulated by Cyclic ADP Ribose"

Partida-Sanchez, S.; Cockayne, D.A.; Monard, S.; Jacobson, E.L.; Oppenheimer, N.; Garvy, B.; Kusser, K.; Goodrich, S.; Howard, M.; Harmsen, A.; Randall, T.D.; Lund, F.E., *Nature Med.*, **7**, 1209 - 1216 (2001): "Cyclic ADP-ribose Production by CD38 Regulates Intracellular Calcium Release, Extracellular Calcium Influx and Chemotaxis in Neutrophils and is Required for Bacterial Clearance *In Vivo*"

Walseth, T.F.; Lee, H.C., *Biochim. Biophys. Acta*, **1178**, 235 - 242 (1993) "Synthesis and Characterization of Antagonists of Cyclic-ADP-ribose-induced Ca²⁺ Release"